Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT04455841 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04455841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04455841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
March 19, 2021
Completion date
September 8, 2026
Enrollment
84 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis